AMH, Glucose Intolerance and Metabolic Syndrome in PCOS

Polycystic Ovary Syndrome Clinical Trial

Official title: Anti-Müllerian Hormone and Its Association With Glucose Intolerance and Metabolic Syndrome in Women With Polycystic Ovary Syndrome

Status Recruiting

Clinical Trial Summary

Association between serum anti-Mullerian hormone (AMH) level and prevalence of glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS)

Clinical Trial Description

• To study the association between serum anti-Mullerian hormone (AMH) level and glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS).

• Glucose intolerance is detected by 2-hours 75 gram oral glucose tolerance test (OGTT).

• Metabolic syndrome is diagnosed by using the Harmonized criteria; the presence of any 3 of 5 following risk factors constitutes a diagnosis of metabolic syndrome.

1. Elevated waist circumference (> 80 cm in Asian women)

2. Elevated triglycerides (> 150 mg/dL)

3. Reduced HDL-cholesterol (< 50 mg/dL)

4. Elevated blood pressure )systolic > 130 and/or diastolic > 85 mmHg)

5. Elevated fasting glucose ( > 100 mg/dL)

• Percentage of glucose intolerance and metabolic syndrome in PCOS women as well was any differences in parameters between PCOS patients with and without glucose intolerance and metabolic syndrome will be analysed. ;

Related Conditions & MeSH terms

• Glucose Intolerance
• Metabolic Syndrome X
• Polycystic Ovary Syndrome
• Syndrome

• NCT number: NCT02676518
• Study type: Observational
• Source: Chulalongkorn University
• Contact: Wasamon Tunsuparp, MD
• Phone: 66850658502
• Email: wasamontun@gmail.com
• Status: Recruiting
• Phase: N/A
• Start date: April 2015
• Completion date: May 2016